Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

Two days af­ter Kite Phar­ma founder Arie Bellde­grun told a fed­er­al court­room that a meet­ing he had with a Memo­r­i­al Sloan Ket­ter­ing ex­ec­u­tive wasn’t about li­cens­ing their im­munother­a­py patent, Kite’s ex-CEO Aya Jakobovits said it was.

The ad­mis­sion came Tues­day dur­ing cross-ex­am­i­na­tion in a patent in­fringe­ment case that fea­tures two of the biggest can­cer biotechs and some of the most well-known names in Amer­i­can med­i­cine.

Jakobovits ini­tial­ly said she was not in at­ten­dance, didn’t know it was go­ing to hap­pen and didn’t know what took place, ac­cord­ing to Law360. But then the plain­tiff’s lawyer hand­ed her a doc­u­ment – whose con­tents were not pub­licly re­vealed – and asked again if she learned af­ter-the-fact that the meet­ing in­volved a po­ten­tial patent li­cense.

“Yes,” Jakobovits even­tu­al­ly said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER